These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8057274)

  • 1. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.
    Zimmerman DM; Gidda JS; Cantrell BE; Schoepp DD; Johnson BG; Leander JD
    J Med Chem; 1994 Jul; 37(15):2262-5. PubMed ID: 8057274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
    Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
    Thomas JB; Atkinson RN; Rothman RB; Fix SE; Mascarella SW; Vinson NA; Xu H; Dersch CM; Lu Y; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2001 Aug; 44(17):2687-90. PubMed ID: 11495579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
    Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
    Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.
    Zimmerman DM; Leander JD; Cantrell BE; Reel JK; Snoddy J; Mendelsohn LG; Johnson BG; Mitch CH
    J Med Chem; 1993 Oct; 36(20):2833-41. PubMed ID: 8410998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
    Mitch CH; Leander JD; Mendelsohn LG; Shaw WN; Wong DT; Cantrell BE; Johnson BG; Reel JK; Snoddy JD; Takemori AE
    J Med Chem; 1993 Oct; 36(20):2842-50. PubMed ID: 8410999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of a new series of 2alpha-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as mu-selective opioid antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; DeHaven RN; Dolle RE
    Bioorg Med Chem Lett; 2006 Feb; 16(4):864-8. PubMed ID: 16298525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
    Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
    Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alvimopan.
    Neary P; Delaney CP
    Expert Opin Investig Drugs; 2005 Apr; 14(4):479-88. PubMed ID: 15882122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.
    Le Bourdonnec B; Belanger S; Cassel JA; Stabley GJ; DeHaven RN; Dolle RE
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4459-62. PubMed ID: 14643346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
    Hiebel AC; Lee YS; Bilsky E; Giuvelis D; Deschamps JR; Parrish DA; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Partilla JS; Rothman RB; Cheng K; Jacobson AE; Rice KC
    J Med Chem; 2007 Aug; 50(16):3765-76. PubMed ID: 17625813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.
    Carroll FI; Dolle RE
    ChemMedChem; 2014 Aug; 9(8):1638-54. PubMed ID: 24981721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
    Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
    J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.